naire" (PBQ), both containing identical items with different wording. Data were obtained from two studies, one being a cross-sectional study on nϭ2,009 patients, the other a prospective observational therapeutic study on nϭ93 patients. Treatment goals and benefits were used to calculate the overall preference-based Patient Benefit Index (PBI). RESULTS: In both studies, the PNQ showed a variety of high therapeutic needs from the perspective of the psoriasis patients. The PBQ questionnaire revealed that under routine treatment only a part of the patient-defined goal were achieved. The resulting PBI depended on the treatment applied. Higher values were observed in systemic treatments, in particular in biologics. The PBI was feasible with a rate of missing values Յ1.5% in PNQ and Յ2.0% in PBQ. The subscales of the PBI were internally consistent (Cronbach's alpha ϭ 0.68 -0.87). The PBI showed satisfying convergent validity with respect to correlation with changes in QoL (delta DLQI) and PASI. Moreover, correlation with separate single items on treatment benefit (anchoring variables) was markedly high (rϭ0.75, rϭ0.65, pϽ0.001). CONCLUSIONS: The Patient Benefit Index (PBI) is a valid, reliable and suitable instrument for the assessment of patient-reported benefit in the treatment of psoriasis. 
OBJECTIVES:
Although there are a range of established outcomes measures for psoriasis in general, there has been a lack of valid instruments for nail psoriasis (NPso). Therefore, we developed and validated the three-component tool "Nail Assessment in Psoriasis and Psoriatic Arthritis" (NAPPA) including health-related quality of life (NAPPA-QoL), patient-relevant treatment benefit (NAPPA-PBI) and clinical severity (NAPPA-CLIN). METHODS: The NAPPA tool was developed by a multinational expert group involving dermatologists, psychologists, statisticians, and patients. Development included the following steps: 1) Open item collection on patient-relevant impairments and needs in nϭ120 patients in 2 countries (D, USA); 2) item development by an expert panel including patients; 3) double forward and backward translations with subsequent translators' and developers' conferences; 4) feasibility testing of the pilot questionnaire in nϭ55 patients in 4 countries (D, USA, Canada, UK) with subsequent questionnaire refinement; 5) longitudinal feasibility and validation study in nϭ203 patients from 6 countries (Germany, USA, Denmark, Japan, Italy, Spain). RESULTS: Open item collection generated 692 single items with redundant content which could be condensed to 20 items for the NAPPA-QoL and 24 items for the NAPPA-PBI. Most patients rated the final questionnaires as feasible, i.e. the purpose was clear to them (95.0%), instructions and questions were comprehensible (83.6% / 89.1%), and all relevant areas were covered (87.1%). NAPPA-QoL and -PBI correlated moderately with clinical outcomes (PASI, NAPSI) but markedly with other QoL questionnaires (EQ-5D, DLQI). Sensitivity to change and internal consistency were good. Clinical severity (NAPPA-CLIN) was measured with a two-digit solution which correlated highly (rϾ0.9) with NAPSI but which can be assessed much more time-efficiently. CONCLUSIONS: With the modular NAPPA outcomes tool, clinical and patient-reported outcomes in nail psoriasis can be measured validly and reliably. Thus, it can be recommended for usage in international clinical studies and daily practice.
PSS27 DO SCARS IMPACT BEYOND JUST APPEARANCE? A REPORT OF THE CONTENT ELICITATION (CE) PHASE IN THE DEVELOPMENT OF THE PATIENT REPORTED SCAR EVALUATION QUESIONNAIRE (PR-SEQ)
Pleil A 1 , Jensen J 
OBJECTIVES:
Currently available scar assessment tools focus on the appearance and symptoms of scars but avoid the complete scar experience. Additionally, existing instruments lack evidence or documentation (or both) of their development (e.g., content validity) and performance (e.g., reliability, construct-related validity, and responsiveness), and it is unlikely they would meet current regulatory requirements for labeling. The objective of the present work was to conduct qualitative research with patients to better understand scar appearance, symptoms, and impacts, and to use those results to inform the development of a content-valid PRO instrument for use in clinical trials. METHODS: Eight physicians (3 dermatologists and 5 plastic surgeons) recruited subjects to participate in the CE research activities. Each subject (aged 18 to 65) was required to have a linear surgical (cosmetic or non-cosmetic) scar below the neck. Subjects with burn scars were excluded as were subjects with significant medical comorbidities. The interviews were conducted in multiple cities in the United States, transcribed, and used to derive the scar questionnaire items. RESULTS: A total of 43 interviews across five surgery types were conducted to elicit information regarding their experiences with their disfiguring scar. During the CE interviews, the most important and relevant concepts patients used to describe scar appearance were color, size (height, width, thickness), and texture. The most important and relevant scar symptom concepts reported were itchiness and pain. The most important, relevant, and bothersome scar impact concepts were limitations of wearing certain clothing and feeling self-conscious, sad, and less attractive because of the scar. CONCLUSIONS: The CE interviews provided rich information about how patients perceive and experience their scars which extends beyond the typical appearance dimensions. This work is fundamental in providing the basis for the conceptual framework of the scar experience and the first steps in the development of the PR-SEQ. 
PSS28 LONG-TERM IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AFTER TRANSITION FROM METHOTREXATE TO USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS: TRANSIT WEEK 52 RESULTS

Reich
OBJECTIVES:
We describe Week 52 quality of life outcomes following immediate or gradual transition to ustekinumab in psoriasis patients with inadequate response to methotrexate in the Phase IV TRANSIT study (NCT01059773). METHODS: In this 52-week, open-label trial, 490 patients with moderate-to-severe plaque psoriasis despite treatment with methotrexate (10 -25mg/week for Ն8 weeks) were randomised 1:1 to ustekinumab with immediate cessation of methotrexate (Arm1), or 4 weeks' overlap with decreasing methotrexate dose (Arm2). Ustekinumab was administered according to label: 45mg in patients Յ100kg or 90mg if Ͼ100kg. Patients Յ100kg not achieving adequate response (Psoriasis Area Severity Index decrease from baseline Ն75% [PASI 75]) at Weeks 28 or 40 were dose escalated to 90mg. RESULTS: A total of 244 patients were treated in Arm1 and 245 in Arm2; 92% and 90%, respectively, completed 52 weeks' therapy. Median baseline Dermatology Life Quality Index (DLQI) was 8 and 9 in Arms1 and 2, respectively, decreasing to 1 (both arms) at Weeks 16 and 52. At Week 52 in Arms1 and 2, respectively, 61% and 62% of patients had a DLQI reduction Ն5 points; 62% and 67% had DLQI 0 or 1. Median DLQI scores were low at Week 28 among patients who dose escalated; In patients with moderate-to-severe psoriasis, ustekinumab use was associated with clinically relevant improvements in patient-reported outcomes, irrespective of whether patients were transitioned with immediate or gradual cessation of methotrexate. Improvements at Week 16 were sustained to 52 weeks of ustekinumab therapy. Liu Y, Liu CC, Campbell J, Li XY, Hashad Y, Kowalski JW Allergan, Inc., Irvine, CA, USA OBJECTIVES: To investigate whether a 1-line (5 letters) average change in best corrected visual acuity (BCVA) is associated with changes in health-related quality of life (HRQoL) in patients with diabetic macular edema (DME). METHODS: Data from a 12-month randomized trial of dexamethasone intravitreal implant plus laser or laser alone for DME were analyzed. HRQoL was assessed by the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). Patients were categorized into groups based on time-weighted average BCVA change from baseline: worsened (⌬BCVA Յ-5), no change (-5 Ͻ⌬BCVAϽ5) and improved (⌬BCVAՆ5). Average change in VFQ-25 composite score and 11 subscales were compared using ANCOVA analysis controlling for baseline BCVA and VFQ-25 scores. Proportions of patients achieving Ն5-point improvement in VFQ-25 composite score and 4 subscales closely associated with central vision (general vision, near activities, distant activities, and mental health) were also compared. Similar analyses were conducted for subgroups of better-seeing eye (BSE) and worse-seeing eye (WSE) patients, respectively. RESULTS: A total of 252 (18.3% BSE and 81.7% WSE) patients had a mean VFQ-25 composite score of 69.1 at baseline. Compared to the no change BCVA group, the improved group had 3.2-6.7 points (pՅ0.048) greater average changes in VFQ-25 composite score and 4 subscales (general vision, near activities, dependency, and driving ); the corresponding differences were greater (10.2-18.3 points, pՅ0.019) among BSE patients except in general vision. The worsened, no change, and improved BCVA groups showed a statistically different (pՅ0.038) and increasing trend in achieving Ն5-point improvement in the 4 VFQ-25 subscales examined except in distant activities. CONCLUSIONS: Previous literature based on BSE visual acuity has defined minimally important differences in VFQ-25 score ranging from 3 to 5 points. The current study suggests a 1-line average improvement in BCVA was associated with clinically meaningful changes in HRQoL among DME patients.
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